BSE: 532296 | NSE: GLENMARK | Pharmaceuticals & Drugs | Mid Cap
1. Is Glenmark Pharmaceuticals Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Glenmark Pharmaceuticals Ltd is a average quality company.
2. Is Glenmark Pharmaceuticals Ltd undervalued or overvalued?
The key valuation ratios of Glenmark Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
3. Is Glenmark Pharmaceuticals Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Glenmark Pharmaceuticals Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘ
Value Creation Index Colour Code Guide ⓘ
|ROCE % ⓘ||14.8%||11.5%||8%||13.3%||16.4%||10.1%||9.2%||8.8%||10.9%||10.3%||-|
|Value Creation Index ⓘ||0.1||-0.2||-0.4||0.2||0.5||-0.3||-0.3||-0.4||-0.2||-0.2||-|
Growth Parameters ⓘ
Growth Parameters Colour Code Guide ⓘ
|YoY Gr. Rt. %||-||19.6%||12.4%||13.2%||20.1%||-0.1%||8.7%||7.9%||2.9%||12.4%||-|
|Adj EPS ⓘ||23.8||20.2||12.6||26.7||43||26.8||24.2||23.3||35.1||37.8||31.2|
|YoY Gr. Rt. %||-||-14.8%||-38%||113%||60.7%||-37.6%||-9.7%||-3.8%||50.8%||7.7%||-|
|BVPS (₹) ⓘ||102||110||65.7||128.6||159.2||182.6||198.3||214.7||249.6||321.5||349.6|
|Adj Net Profit ⓘ||643||549||341||754||1,212||757||683||657||991||1,067||881|
|Cash Flow from Ops. ⓘ||648||854||482||345||657||1,648||1,324||1,392||1,131||1,109||-|
|Debt/CF from Ops. ⓘ||4.3||3.8||7.9||11.6||7.2||2.8||3.4||3.5||4.1||3.3||-|
CAGR Colour Code Guide ⓘ
|9 Years||5 Years||3 Years||1 Years|
|Adj EPS ⓘ||5.3%||-2.5%||16%||7.7%|
Key Financial Parameters ⓘ
Performance Ratio Colour Code Guide ⓘ
|Return on Equity % ⓘ||24.9||19.1||14.3||27.9||29.9||15.7||12.7||11.3||15.1||13.2||9.3|
|Op. Profit Mgn % ⓘ||21.1||18.5||18.2||19.2||23.2||17.8||16.1||16||19.7||18.9||17.3|
|Net Profit Mgn % ⓘ||13.1||9.3||5.1||10||13.4||8.3||6.9||6.2||9.1||9.1||7.1|
|Debt to Equity ⓘ||1||1.1||2.1||1.1||1.1||0.9||0.8||0.8||0.7||0.4||-|
|Working Cap Days ⓘ||213||219||244||242||219||236||217||201||88||88||0|
|Cash Conv. Cycle ⓘ||96||86||77||60||69||82||66||56||-28||-21||0|
Net Profit is growing at healthy rate in last 3 years 16.02%
Debt to equity has declined versus last 3 years average to 0.40
Return on Equity has declined versus last 3 years average to 9.30%
Sales growth has been subdued in last 3 years 7.64%
Sales growth is not so good in last 4 quarters at 2.74%
|TTM EPS (₹)||55||31.2|
|TTM Sales (₹ Cr.)||7,866||12,386|
|BVPS (₹.) ⓘ||638.5||349.6|
|Reserves (₹ Cr.) ⓘ||17,989||9,836|
|From the Market|
|52 Week Low / High (₹)||348.90 / 487.15|
|All Time Low / High (₹)||1.89 / 1261.95|
|Market Cap (₹ Cr.)||12,406|
|Equity (₹ Cr.)||28.2|
|Face Value (₹)||1|
|Industry PE ⓘ||35.9|
Glenmark Pharmaceuticals Ltd. (GPL) was incorporated in 1977. It was founded with a vision to emerge as a leading integrated research-based, global pharmaceutical company. Its branded generics business has a significant presence in markets across emerging economies including India. It is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in many countries. Glenmark’s key therapy focus areas globally are respiratory, dermatology and oncology. Its API business sells products in many countries including the US, various countries in the EU, South America and India.
India is the largest market in terms of revenue for the organization. The formulations business has five manufacturing facilities; three in India and two overseas. These facilities are approved by several regulatory bodies. The facility at Baddi, Himachal Pradesh, India is also approved by MHRA and USFDA for semi-solids. The overseas facilities are situated in Brazil and the Czech Republic. While the manufacturing facility in Brazil services requirements of the Latin American region, the Czech facility services requirements of the Central Eastern Europe region. Glenmark has also invested in a dedicated R&D facility for formulations development. This R&D centre, situated near Nashik, India is engaged in developing specialty/ branded formulations for global markets.
Business area of the company
The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Specialty Business: Drug Discovery: Glenmark’s ground-breaking drug discovery effort is primarily focused in the areas of inflammation [asthma/COPD, rheumatoid arthritis etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain]. Specialty Business: Formulations Business: Glenmark’s formulations business is currently organized many regions - India, Latin America, Central Eastern Europe and Semi Regulated Markets of Africa/Asia/CIS. The formulations business focuses on therapeutic areas viz. dermatology, anti-infective, respiratory, cardiac, diabetes, gynecology, CNS, and oncology.